Alimera Sciences Names European Management Team

               Alimera Sciences Names European Management Team

PR Newswire

ATLANTA, Nov. 14, 2012

ATLANTA, Nov. 14, 2012 /PRNewswire/ --Alimera Sciences, Inc., (NASDAQ: ALIM)
(Alimera), a biopharmaceutical company that specializes in the research,
development and commercialization of prescription ophthalmic pharmaceuticals,
today announced the appointment of the management team that will oversee
European commercialization of its lead product, ILUVIEN^®. Philip Ashman,
Ph.D., has been named senior vice president and European managing director,
while Eric Teo, MBBS, will serve as vice president and European medical
director and Anne-Marie Swift will serve as vice president and European
marketing director.

"I am delighted to welcome these talented individuals to Alimera. We believe
their broad pharmaceutical experience, and knowledge of the European
ophthalmic market, will be integral to achieving our goal of a successful
launch of the product in Europe," said Dan Myers, president and chief
executive officer, Alimera. "We are confident in this team's ability to drive
not only European sales of ILUVIEN in our initial launch markets, but also the
development of our long term strategy in Europe."

"ILUVIEN is the first sustained release treatment option for the many patients
in Europe suffering from chronic diabetic macular edema (DME) considered
insufficiently responsive to available therapies. It is a very exciting time
to be joining Alimera Sciences and to have the opportunity to lead the
commercial launch of this brand in Europe," said Dr. Ashman. "This is a
significant step for the company and the many patients with chronic DME."

Dr. Ashman brings to Alimera more than 20 years of experience in all aspects
of pharmaceutical management. During his career, he has held numerous
leadership roles, including serving as vice president at Bayer, responsible
for setting strategy and early preparations for specialty medicines. He also
served at Bayer as Regional Business Unit Head (Europe) in Oncology,
responsible for the delivery of oncology sales and profitability targets in
Europe, Canada, the Middle East and Africa. Most recently, he has been
responsible for leadership of the market access strategy in the U.K. for
Bayer, covering numerous therapy areas including ophthalmology. Dr. Ashman
holds a doctorate in biochemistry from the University of London: Royal
Holloway and Bedford, U.K., and a Bachelor of Science degree in biochemistry
from the University College London, U.K.

Following a career as a physician, Eric Teo, MBBS, MBA, FFPM, FRCP, LLM, moved
on to the pharmaceutical industry where he has spent more than 11 years in
various roles in medical and regulatory affairs, most recently serving as
director of global regulatory affairs, health and personal care for Reckitt
Benckiser. While there, he established the European medical and regulatory
team following the company's acquisition of Boots Healthcare and led several
successful European product launches. Dr. Teo trained as a physician at the
University of Melbourne, Australia. He is a Fellow of the Royal College of
Physicians and Surgeons (Glasgow) and a Fellow of the Faculty of
Pharmaceutical Medicine, Royal College of Physicians, U.K. In addition to a
postgraduate diploma in medicine, Dr. Teo alsoholds a MBA from London
Business School and a LLM from BPP Law School, London.

Trained as a registered nurse, Anne-Marie Swift has broad experience as a
senior market leader in ophthalmic pharmaceuticals. Prior to joining Alimera,
Ms. Swift served as European brand director for ophthalmology at Pfizer
Limited, focusing on glaucoma and retina treatments. In this role, she managed
all aspects of marketing for Xalatan^® and Xalacom^® across Europe, including
development of the medical education programs and key opinion leaders for the
brands. Ms. Swift earned a registered general nursing (RGN) degree from St.
Helens and Knowsley School of Nursing, Merseyside, a renal and urology
specialist nursing degree from Oxford School of Nursing, Oxford, and a
Bachelor of Arts in health studies from Oxford Brookes University.

About ILUVIEN^®

ILUVIEN (190 micrograms fluocinolone acetonide intravitreal implant in
applicator) is a sustained release intravitreal implant used to treat patients
with chronic DME considered insufficiently responsive to available therapies.
Each ILUVIEN implant provides a therapeutic effect of up to 36 months by
delivering sustained sub-microgram levels of fluocinolone acetonide (FAc).
ILUVIEN is injected in the back of the patient's eye to a position that takes
advantage of the eye's natural fluid dynamics. The applicator employs a
25-gauge needle, which allows for a self-sealing wound. In Alimera's FAME
Study, the most frequently reported adverse drug reactions included cataract
operation, cataract and increased ocular pressure.

In July 2010, Alimera submitted a Marketing Authorization Application (MAA) to
seven European countries via the Decentralized Procedure (DCP) with the
Medicines and Healthcare products Regulatory Agency of the U.K. (MHRA) serving
as the Reference Member State (RMS). The MAA included data from two Phase 3
pivotal clinical trials for ILUVIEN conducted by Alimera (collectively known
as the FAME Study). The trials involved 956 patients in sites across the
United States, Canada, Europe and India to assess the efficacy and safety of
ILUVIEN for the treatment of DME. At the end of the DCP, a consensus was
reached by the RMS and the other six countries that the MAA for ILUVIEN was
approvable. To date, five of the seven countries, Austria, the United Kingdom,
Portugal, France and Germany, have granted national licenses for ILUVIEN.
ILUVIEN has not been approved by the United States Food and Drug
Administration.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical
company that specializes in the research, development and commercialization of
prescription ophthalmic pharmaceuticals. Alimera Sciences Limited, a wholly
owned subsidiary of Alimera, is headquarters of Alimera's European operations
in London. Presently Alimera is focused on diseases affecting the back of the
eye, or retina. Its primary product, ILUVIEN, is an intravitreal implant
containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with
demonstrated efficacy in the treatment of ocular disease.

Forward Looking Statements

This press release contains "forward-looking statements," within the meaning
of the Private Securities Litigation Reform Act of 1995, regarding, among
other things, Alimera's commercial plans for ILUVIEN in Germany, the UK and
France. Such forward-looking statements are based on current expectations and
involve inherent risks and uncertainties, including factors that could delay,
divert or change any of them, and could cause actual results to differ
materially from those projected in its forward-looking statements. Meaningful
factors which could cause actual results to differ include, but are not
limited to, uncertainty as to Alimera's ability to commercialize, and market
acceptance of, ILUVIEN in the EU, as well as other factors discussed in the
"Risk Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" sections of Alimera's Annual Report on
Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form
10-Q for the quarter ended September 30, 2012, which are on file with the
Securities and Exchange Commission (SEC) and available on the SEC's website at
www.sec.gov. In addition to the risks described above and in Alimera's Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form
8-K and other filings with the SEC, other unknown or unpredictable factors
also could affect Alimera's results. There can be no assurance that the actual
results or developments anticipated by Alimera will be realized or, even if
substantially realized, that they will have the expected consequences to, or
effects on, Alimera. Therefore, no assurance can be given that the outcomes
stated in such forward-looking statements and estimates will be achieved.

All forward-looking statements contained in this press release are expressly
qualified by the cautionary statements contained or referred to herein.
Alimera cautions investors not to rely too heavily on the forward-looking
statements Alimera makes or that are made on its behalf. These forward-looking
statements speak only as of the date of this press release (unless another
date is indicated). Alimera undertakes no obligation, and specifically
declines any obligation, to publicly update or revise any such forward-looking
statements, whether as a result of new information, future events or
otherwise.

For press inquiries:            For investor inquiries:

Katie Brazel, Fleishman-Hillard John Mills, ICR

for Alimera Sciences            for Alimera Sciences

404-739-0150                    310-954-1105

Katie.Brazel@fleishman.com      John.Mills@ICRINC.com



SOURCE Alimera Sciences, Inc.

Website: http://www.alimerasciences.com
 
Press spacebar to pause and continue. Press esc to stop.